MAGE A3/A6 TCR

N/A

Report date: 2026/03/24 20:00:35

Base Information

Drug NameMAGE A3/A6 TCR
Drug Alias Nameanti-MAGE A3/A6 TCRKITE-718
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-Melanoma-associated antigen 3
TargetsMelanoma-associated antigen 3
Therapy Area/IndicationsSolid tumoursKidney NeoplasmsUterine Cervical Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesKite PharmaNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKite PharmaNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsSolid tumoursKidney NeoplasmsUterine Cervical Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A